Digital Twins in Biomanufacturing: Data Architecture and Scale-Up Simulation

Running a thousand virtual scale-up simulations before touching a single real-world valve is no longer a theoretical ambition. Digital twins in biomanufacturing have matured from concept to operational tool, linking process analytical technology (PAT) sensors, laboratory information management systems (LIMS), and manufacturing execution systems (MES) into a unified data architecture that makes predictive scale-up simulation practical at development and commercial scale alike.

How a bioprocess digital twin functions in biomanufacturing

A bioprocess digital twin is a software-based virtual representation of a physical manufacturing process, calibrated continuously against real-world data. Unlike static simulation models, a functioning digital twin maintains a live connection to the physical process through sensor feeds, integrating temperature, pH, dissolved oxygen, metabolite concentrations, and other critical process parameters to update its predictive state in real time. This dynamic coupling distinguishes a digital twin from a digital model, which generates only static prognoses, or a digital shadow, which mirrors actual process status without generating forward predictions.

The architecture required to sustain this capability is layered. At the base sits the data collection layer: PAT instruments such as Raman probes and capacitance sensors generating continuous process streams, complemented by at-line and offline analytical measurements. Above that, LIMS and MES platforms serve as the connective tissue, routing process data to the model environment and returning control outputs. Research into scalable bioprocess software demonstrates that effective integration requires standardized communication protocols capable of handling data from instruments, LIMS, and design-of-experiments packages within a unified environment.

Building this connectivity is the foundational engineering challenge of digital twin implementation. A review of analytical infrastructure requirements identifies the relevant data streams explicitly: time-series process values, spectral outputs, images, electronic laboratory notebook (ELN) entries, and LIMS and MES records must all be integrated and analyzed holistically. The same review notes that standardized analysis platforms and agreed-upon dashboard formats for knowledge display are prerequisites that many facilities have not yet met.

Data architecture for digital twin connectivity

Integrating a digital twin into a biomanufacturing environment requires interoperability across three system layers: PAT instrumentation, LIMS, and MES. Each generates data at a different frequency and often in proprietary formats that must be harmonized before the twin can consume them. LIMS platforms manage offline and at-line analytical results, including titer measurements and metabolite panels; MES systems capture batch records and process step outcomes; PAT dashboards aggregate real-time spectroscopic and electrochemical feeds. A digital twin drawing on all three must operate through standardized interfaces that avoid creating vendor dependency at the integration layer. The Pharma 4.0 digital integration landscape illustrates how eliminating data silos is a prerequisite for this kind of connected operation.

Table 1. Digital twin data source types and their roles in a connected biomanufacturing architecture.

Ensuring data integrity across this architecture requires adherence to 21 CFR Part 11 requirements for electronic records and audit trails. The FDA's PAT guidance frames the digital twin's sensor data streams as legitimate inputs to process understanding and quality assurance, directly supporting the use of virtual models in regulatory submissions.

Scale-up simulation and process parameter modeling

The primary operational value of a digital twin in bioprocess development lies in its ability to simulate scale-up transitions before they occur in the physical facility. Translating a process from a 10-liter development bioreactor to a 2,000-liter production vessel introduces changes in mixing dynamics, oxygen transfer rates, carbon dioxide accumulation, and shear stress profiles that can destabilize cell culture performance in ways that are difficult to predict from small-scale data alone. Digital twins address this by virtualizing the process parameter space at target scale, allowing engineers to stress-test feeding strategies, agitation profiles, and gas sparging regimes against the model before committing any physical run.

This approach is enabled by concatenated unit operation models, in which individual process steps are represented as separate model components linked in sequence. Research into integrated bioprocess models describes how Monte Carlo applications leverage these linked models to simulate error propagation across the entire process, from upstream cell culture through downstream purification, based on the statistical variation of input parameters. By quantifying how variability at one stage cascades through subsequent steps, process development teams can identify which parameters are most critical to lock before scale-up begins.

Hybrid modeling approaches, combining mechanistic equations describing known biological and physical phenomena with machine learning models trained on historical process data, are extending the accuracy and transferability of these simulations. A mammalian cell culture study using Chinese hamster ovary (CHO) cells demonstrated that this control framework is flexible and transferable across different cell culture systems while enabling higher predicted antibody production yields relative to open-loop operation. The next-generation process analytics driving this capability are explored in coverage of real-time data and PAT frameworks across biomanufacturing settings.

Digital twin compliance: regulatory and quality-by-design requirements

Digital twin deployment in biopharmaceutical manufacturing does not exist outside regulatory expectations. The ICH Q13 guidance, adopted at Step 4 in November 2022 and published by the FDA in March 2023, addresses the use of process models and real-time monitoring as components of continuous manufacturing control strategies. Digital twins that feed verified process parameter models into control loops align with quality-by-design principles, particularly the expectation that manufacturers demonstrate sufficient process understanding to predict and prevent deviations before they affect product quality.

A 2025 pharmaceutical manufacturing review confirms that real-time digital twin feedback can guide in-process adjustments to temperature, pH, and nutrient concentrations during cell culture, enabling manufacturers to respond to critical quality attribute deviations proactively. The digital twin's regulatory value depends on the validation state of its underlying models: PAT data fusion research notes that transfer into the regulated pharmaceutical sector has been constrained by the validation requirements each model layer must satisfy. Analytical characterization data from platforms covered in proteomics and mass spectrometry workflows increasingly feed into the quality attribute monitoring that digital twin control strategies rely on.

Manufacturers should document the model development lifecycle, including training data provenance, validation experiments, and change control procedures, as part of a digital quality management system. The digital twin must be treated as regulated software wherever it generates data used in batch disposition decisions.

Realizing the value of digital twins in biomanufacturing data integration

Practical returns from digital twin implementation concentrate on two areas: reducing failed scale-up attempts and compressing process development cycles. By virtualizing the process parameter space before physical experiments are committed, development teams eliminate engineering runs that serve only to confirm expected behavior, runs that are expensive at pilot scale and prohibitively costly at commercial scale. The ability to simulate thousands of parameter combinations in silico compresses what would otherwise be a multi-year process characterization program.

The prerequisite for realizing these gains is the connected data architecture that feeds the digital twin continuously. Facilities that have not standardized their interfaces across PAT, LIMS, and MES layers will find that data availability, not modeling capability, is the binding constraint on deployment. Investment in data architecture is not upstream overhead: it is the foundational engineering work that determines how much of the digital twin's simulation capability a facility can capture.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.